Prostatype Genomics AB: Rights issue registered and trading in paid subscription units ceases

2024-01-16 09:30

Prostatype Genomics AB ("Prostatype Genomics" or the "Company") has completed a rights issue of units, consisting of shares and warrants of series 3, that closed on January 5, 2024. The rights issue is now registered with the Swedish Companies Registration Office and the last day of trading in paid subscription units (“BTU”) is January 17, 2024. The record date is January 19, 2024, after which BTUs are converted into shares and warrants of series 3 (“TO3”) on January 23, 2024. The new shares and TO3 warrants will be listed on Nasdaq First North Growth Market and the last day of trading in TO3 is April 17, 2024.

For further information about Prostatype Genomics, please contact:

Fredrik Persson, CEO

Telephone: +46 (0) 73 049 77 01.

e-mail: fredrik.persson@prostatypegenomics.com

Certified Adviser

Carnegie Investment Bank AB (publ), +46 (0)73 856 4265, certifiedadviser@carnegie.se

About Prostatype Genomics AB

Prostatype® is a genetic test that is available to patients and treating urologists as a supplementary decision support tool to answer the question of radical treatment or no radical treatment of prostate cancer. The test is developed by a research group at Karolinska Institutet and is provided by Prostatype Genomics AB.